186 related articles for article (PubMed ID: 17987036)
1. Interleukin-6 trans signalling enhances photodynamic therapy by modulating cell cycling.
Wei LH; Baumann H; Tracy E; Wang Y; Hutson A; Rose-John S; Henderson BW
Br J Cancer; 2007 Dec; 97(11):1513-22. PubMed ID: 17987036
[TBL] [Abstract][Full Text] [Related]
2. Interleukin-6-resistant melanoma cells exhibit reduced activation of STAT3 and lack of inhibition of cyclin E-associated kinase activity.
Böhm M; Schulte U; Funk JO; Raghunath M; Behrmann I; Kortylewski M; Heinrich PC; Kues T; Luger TA; Schwarz T
J Invest Dermatol; 2001 Jul; 117(1):132-40. PubMed ID: 11442760
[TBL] [Abstract][Full Text] [Related]
3. The role of IL-6 trans-signaling in vascular leakage: implications for ovarian hyperstimulation syndrome in a murine model.
Wei LH; Chou CH; Chen MW; Rose-John S; Kuo ML; Chen SU; Yang YS
J Clin Endocrinol Metab; 2013 Mar; 98(3):E472-84. PubMed ID: 23348396
[TBL] [Abstract][Full Text] [Related]
4. IL-6 trans-signalling directly induces RANKL on fibroblast-like synovial cells and is involved in RANKL induction by TNF-alpha and IL-17.
Hashizume M; Hayakawa N; Mihara M
Rheumatology (Oxford); 2008 Nov; 47(11):1635-40. PubMed ID: 18786965
[TBL] [Abstract][Full Text] [Related]
5. Interleukin-6 trans-signalling induces vascular endothelial growth factor synthesis partly via Janus kinases-STAT3 pathway in human mesothelial cells.
Yang X; Lin A; Jiang N; Yan H; Ni Z; Qian J; Fang W
Nephrology (Carlton); 2017 Feb; 22(2):150-158. PubMed ID: 26869278
[TBL] [Abstract][Full Text] [Related]
6. Soluble interleukin-6 receptor (sIL-6R) makes IL-6R negative T cell line respond to IL-6; it inhibits TNF production.
Igaz P; Horváth A; Horváth B; Szalai C; Pállinger E; Rajnavölgyi E; Tóth S; Rose-John S; Falus A
Immunol Lett; 2000 Mar; 71(3):143-8. PubMed ID: 10722865
[TBL] [Abstract][Full Text] [Related]
7. Photodynamic therapy causes cross-linking of signal transducer and activator of transcription proteins and attenuation of interleukin-6 cytokine responsiveness in epithelial cells.
Liu W; Oseroff AR; Baumann H
Cancer Res; 2004 Sep; 64(18):6579-87. PubMed ID: 15374971
[TBL] [Abstract][Full Text] [Related]
8. Essential roles of IL-6 trans-signaling in colonic epithelial cells, induced by the IL-6/soluble-IL-6 receptor derived from lamina propria macrophages, on the development of colitis-associated premalignant cancer in a murine model.
Matsumoto S; Hara T; Mitsuyama K; Yamamoto M; Tsuruta O; Sata M; Scheller J; Rose-John S; Kado S; Takada T
J Immunol; 2010 Feb; 184(3):1543-51. PubMed ID: 20042582
[TBL] [Abstract][Full Text] [Related]
9. Oncostatin M and interleukin 6 inhibit cell cycle progression by prevention of p27kip1 degradation in HepG2 cells.
Klausen P; Pedersen L; Jurlander J; Baumann H
Oncogene; 2000 Jul; 19(32):3675-83. PubMed ID: 10951574
[TBL] [Abstract][Full Text] [Related]
10. Interleukin-10 attenuates tumour growth by inhibiting interleukin-6/signal transducer and activator of transcription 3 signalling in myeloid-derived suppressor cells.
Lee BR; Kwon BE; Hong EH; Shim A; Song JH; Kim HM; Chang SY; Kim YJ; Kweon MN; Youn JI; Ko HJ
Cancer Lett; 2016 Oct; 381(1):156-64. PubMed ID: 27431309
[TBL] [Abstract][Full Text] [Related]
11. Interleukin-6 trans-signalling in chronic inflammation and cancer.
Scheller J; Ohnesorge N; Rose-John S
Scand J Immunol; 2006 May; 63(5):321-9. PubMed ID: 16640655
[TBL] [Abstract][Full Text] [Related]
12. Interleukin-6 biology is coordinated by membrane-bound and soluble receptors: role in inflammation and cancer.
Rose-John S; Scheller J; Elson G; Jones SA
J Leukoc Biol; 2006 Aug; 80(2):227-36. PubMed ID: 16707558
[TBL] [Abstract][Full Text] [Related]
13. Humanised antihuman IL-6R antibody with interferon inhibits renal cell carcinoma cell growth in vitro and in vivo through suppressed SOCS3 expression.
Oguro T; Ishibashi K; Sugino T; Hashimoto K; Tomita S; Takahashi N; Yanagida T; Haga N; Aikawa K; Suzutani T; Yamaguchi O; Kojima Y
Eur J Cancer; 2013 May; 49(7):1715-24. PubMed ID: 23274199
[TBL] [Abstract][Full Text] [Related]
14. Interleukin-6/soluble interleukin-6 receptor signaling attenuates proliferation and invasion, and induces morphological changes of a newly established pleomorphic malignant fibrous histiocytoma cell line.
Nakanishi H; Yoshioka K; Joyama S; Araki N; Myoui A; Ishiguro S; Ueda T; Yoshikawa H; Itoh K
Am J Pathol; 2004 Aug; 165(2):471-80. PubMed ID: 15277221
[TBL] [Abstract][Full Text] [Related]
15. The classic signalling and trans-signalling of interleukin-6 are both injurious in podocyte under high glucose exposure.
Lei CT; Su H; Ye C; Tang H; Gao P; Wan C; He FF; Wang YM; Zhang C
J Cell Mol Med; 2018 Jan; 22(1):251-260. PubMed ID: 28881473
[TBL] [Abstract][Full Text] [Related]
16. Interleukin-6 inhibits cell proliferation in a rat model of hepatocellular carcinoma.
Moran DM; Mayes N; Koniaris LG; Cahill PA; McKillop IH
Liver Int; 2005 Apr; 25(2):445-57. PubMed ID: 15780071
[TBL] [Abstract][Full Text] [Related]
17. Pharmacologic IL-6Rα inhibition in cholangiocarcinoma promotes cancer cell growth and survival.
Kleinegger F; Hofer E; Wodlej C; Golob-Schwarzl N; Birkl-Toeglhofer AM; Stallinger A; Petzold J; Orlova A; Krassnig S; Reihs R; Niedrist T; Mangge H; Park YN; Thalhammer M; Aigelsreiter A; Lax S; Garbers C; Fickert P; Rose-John S; Moriggl R; Rinner B; Haybaeck J
Biochim Biophys Acta Mol Basis Dis; 2019 Feb; 1865(2):308-321. PubMed ID: 30419338
[TBL] [Abstract][Full Text] [Related]
18. Combination of interleukin-6 and soluble interleukin-6 receptors induces differentiation and activation of JAK-STAT and MAP kinase pathways in MG-63 human osteoblastic cells.
Nishimura R; Moriyama K; Yasukawa K; Mundy GR; Yoneda T
J Bone Miner Res; 1998 May; 13(5):777-85. PubMed ID: 9610741
[TBL] [Abstract][Full Text] [Related]
19. The designer cytokine hyper-interleukin-6 is a potent activator of STAT3-dependent gene transcription in vivo and in vitro.
Rakemann T; Niehof M; Kubicka S; Fischer M; Manns MP; Rose-John S; Trautwein C
J Biol Chem; 1999 Jan; 274(3):1257-66. PubMed ID: 9880494
[TBL] [Abstract][Full Text] [Related]
20. SKLB188 inhibits the growth of head and neck squamous cell carcinoma by suppressing EGFR signalling.
Barzegar M; Ma S; Zhang C; Chen X; Gu Y; Shang C; Jiang X; Yang J; Nathan CA; Yang S; Huang S
Br J Cancer; 2017 Oct; 117(8):1154-1163. PubMed ID: 28873083
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
